Related Experiment Videos
Chronic lymphocytic leukaemia treatment
1Postgraduate School of Haematology Farreras Valentí, Hospital Clínic, Barcelona, Spain.
Blood Reviews
|September 1, 1993
Summary
Advances in chronic lymphocytic leukemia (CLL) treatment involve risk stratification for personalized therapy. Early-stage patients with favorable prognosis may not require immediate treatment, unlike those with poor prognostic features.
Area of Science:
- Hematology
- Oncology
- Clinical Medicine
Background:
- Chronic lymphocytic leukemia (CLL) understanding has advanced, leading to new treatment strategies.
- Risk stratification is crucial for determining optimal CLL treatment efficacy.
- Current advances enable more rational treatment decisions for CLL patients.
Purpose of the Study:
- To review current understanding of CLL natural history and prognosis.
- To discuss the role of new drugs and treatment strategies in CLL.
- To outline treatment approaches based on patient risk factors.
Main Methods:
- Review of current literature on CLL natural history, prognosis, and treatment.
- Analysis of clinical trial data stratified by patient risk factors.
- Discussion of established and novel therapeutic agents for CLL.
Main Results:
- Early-stage CLL patients (Binet A, Rai 0) with favorable features have long survival and may not need immediate treatment.
- Patients with poor prognostic features (advanced stage, diffuse infiltration, high lymphocyte levels) have <5-year median survival and require treatment.
- Chlorambucil remains a primary treatment, but fludarabine and 2-chlorodeoxyadenosine show promise, especially for refractory cases.
Conclusions:
- Treatment decisions for CLL should be individualized based on prognostic factors.
- While new agents offer promise, cure remains rare in CLL.
- Specialized treatments and bone marrow transplants are being investigated for specific CLL patient groups.